Literature DB >> 22298593

The dark side of E2F1: in transit beyond apoptosis.

David Engelmann1, Brigitte M Pützer.   

Abstract

E2F1 plays a critical role in cell-cycle progression and the induction of apoptosis in response to DNA damage. The latest evidence has uncovered that this tumor suppressor is most relevant for cancer progression and chemoresistance. Increased abundance of E2F1 triggers invasion and metastasis by activating growth receptor signaling pathways, which in turn promote an antiapoptotic tumor environment. The data shed light on the molecular mechanisms underlying E2F1-induced prometastatic activity and predict its radical switch from a mediator of cell death toward an accelerator of tumor progression. This raises the perspective of new drug targets at late-stage cancer. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22298593     DOI: 10.1158/0008-5472.CAN-11-2575

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  83 in total

1.  Deregulation of Rb-E2F1 axis causes chromosomal instability by engaging the transactivation function of Cdc20-anaphase-promoting complex/cyclosome.

Authors:  Somsubhra Nath; Abhishek Chowdhury; Sanjib Dey; Anirban Roychoudhury; Abira Ganguly; Dibyendu Bhattacharyya; Susanta Roychoudhury
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

Review 2.  The Untranslated Regions of mRNAs in Cancer.

Authors:  Samantha L Schuster; Andrew C Hsieh
Journal:  Trends Cancer       Date:  2019-03-22

3.  Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype.

Authors:  Natalie E Simpson; Volodymyr P Tryndyak; Marta Pogribna; Frederick A Beland; Igor P Pogribny
Journal:  Epigenetics       Date:  2012-11-01       Impact factor: 4.528

4.  E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B.

Authors:  David Engelmann; Deborah Mayoli-Nüssle; Christian Mayrhofer; Katharina Fürst; Vijay Alla; Anja Stoll; Alf Spitschak; Kerstin Abshagen; Brigitte Vollmar; Sophia Ran; Brigitte M Pützer
Journal:  J Mol Cell Biol       Date:  2013-09-06       Impact factor: 6.216

5.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

6.  Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells.

Authors:  Michael R Epis; Keith M Giles; Felicity C Kalinowski; Andrew Barker; Ronald J Cohen; Peter J Leedman
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

7.  Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression.

Authors:  Han Xu; Kexin Xu; Housheng H He; Chongzhi Zang; Chen-Hao Chen; Yiwen Chen; Qian Qin; Su Wang; Chenfei Wang; Shengen Hu; Fugen Li; Henry Long; Myles Brown; X Shirley Liu
Journal:  Mol Cancer Res       Date:  2015-12-09       Impact factor: 5.852

8.  The Many Faces of MDM2 Binding Partners.

Authors:  Maurisa F Riley; Guillermina Lozano
Journal:  Genes Cancer       Date:  2012-03

9.  Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis.

Authors:  M F Montenegro; L Sánchez-Del-Campo; R González-Guerrero; E Martínez-Barba; A Piñero-Madrona; J Cabezas-Herrera; J N Rodríguez-López
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

Review 10.  Programming cancer cells for high expression levels of Mcl1.

Authors:  Franziska Ertel; Mai Nguyen; Anne Roulston; Gordon C Shore
Journal:  EMBO Rep       Date:  2013-03-12       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.